SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Walmart’s Director of Machine Learning on the future of the domain

IANUA Market launches Israel arm to connect investors to global network

Jensen Huang: "Laws of physics" limit Nvidia’s chip ramp as AI demand surges

Elron Ventures cashes out IronScales stake for $26M as PSG increases its holding

Buzz

Most popular

Daily

Weekly

1

Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months

2

Claroty veterans launch Twine with $12M in Seed funding from Dell and Wiz founders to deploy AI cyber workers

3

Salesforce seals $1.9 billion cash deal to acquire cloud backup company Own

4

Prompt Security raises $18 million Series A to protect enterprises from GenAI risks

5

Salesforce to slash jobs at Own after $1.9B acquisition finalized

CytoReason

4 stories about CytoReason

דוד הראל מייסד מנכ"ל CytoReason

CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models

17.07.24|Meir Orbach

The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.

מייסדי סייטוריזן, מימין: דוד הראל, פרופ' שי שן-אור, אלינה סטרוסבצקי, רנו גוז'ו

CytoReason raises $20 million from Pfizer for AI drug discovery and development platform

20.09.22|Meir Orbach

Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years

David Harel CytoReason

CytoReason enters Japanese market with SPI partnership

30.09.21|James Spiro

This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development

בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason

10.01.19|Lilach Baumer

Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars